AU2001273063A1 - Stabilized interleukin 2 - Google Patents

Stabilized interleukin 2

Info

Publication number
AU2001273063A1
AU2001273063A1 AU2001273063A AU7306301A AU2001273063A1 AU 2001273063 A1 AU2001273063 A1 AU 2001273063A1 AU 2001273063 A AU2001273063 A AU 2001273063A AU 7306301 A AU7306301 A AU 7306301A AU 2001273063 A1 AU2001273063 A1 AU 2001273063A1
Authority
AU
Australia
Prior art keywords
interleukin
stabilized
stabilized interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001273063A
Inventor
Rajiv Nayar
Michael A. Shearer
Wei Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Bayer AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24424265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001273063(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer AG, Bayer Corp filed Critical Bayer AG
Publication of AU2001273063A1 publication Critical patent/AU2001273063A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Train Traffic Observation, Control, And Security (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Sub-Exchange Stations And Push- Button Telephones (AREA)
AU2001273063A 2000-06-28 2001-06-27 Stabilized interleukin 2 Abandoned AU2001273063A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/605,577 US6689353B1 (en) 2000-06-28 2000-06-28 Stabilized interleukin 2
US09/605,577 2000-06-28
PCT/US2001/020675 WO2002000243A2 (en) 2000-06-28 2001-06-27 Stabilized interleukin 2

Publications (1)

Publication Number Publication Date
AU2001273063A1 true AU2001273063A1 (en) 2002-01-08

Family

ID=24424265

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001273063A Abandoned AU2001273063A1 (en) 2000-06-28 2001-06-27 Stabilized interleukin 2

Country Status (24)

Country Link
US (1) US6689353B1 (en)
EP (1) EP1370280B1 (en)
JP (3) JP5522878B2 (en)
KR (1) KR100799402B1 (en)
CN (1) CN1523997B (en)
AR (1) AR029139A1 (en)
AU (1) AU2001273063A1 (en)
BR (1) BR0112101B1 (en)
CA (1) CA2413334C (en)
CO (1) CO5290308A1 (en)
CU (1) CU23536A3 (en)
DE (1) DE60142412D1 (en)
DO (1) DOP2001000197A (en)
EC (1) ECSP014106A (en)
ES (1) ES2344729T3 (en)
HN (1) HN2001000139A (en)
IL (2) IL153587A0 (en)
MX (1) MXPA03000046A (en)
MY (1) MY128629A (en)
PE (1) PE20020127A1 (en)
SV (1) SV2002000512A (en)
TW (1) TWI235063B (en)
UY (1) UY26805A1 (en)
WO (1) WO2002000243A2 (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8531276B2 (en) * 2000-03-15 2013-09-10 Logitech Europe S.A. State-based remote control system
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
AU2003268664A1 (en) * 2002-09-26 2004-04-19 Shionogi And Co., Ltd. Stabilized protein compositions
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
RU2418633C2 (en) * 2004-04-08 2011-05-20 Байоматрика, Инк. Integration of specimens storage and control in biomedical sciences
KR20070110901A (en) * 2005-03-04 2007-11-20 다이나박스 테크놀로지 코퍼레이션 Vaccines comprising oligonucleotides having immunostimulatory sequences(iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
CA2643693A1 (en) * 2006-03-10 2007-09-20 Dyax Corp. Formulations for ecallantide
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
NO347644B1 (en) 2006-05-04 2024-02-12 Boehringer Ingelheim Int Polymorphs
MX2009012964A (en) * 2007-06-01 2010-01-14 Acologix Inc High temperature stable peptide formulation.
AR071175A1 (en) 2008-04-03 2010-06-02 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO
DE102008023820A1 (en) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg An agent for the treatment and / or prophylaxis of an autoimmune disease and for the production of regulatory T cells
KR20200118243A (en) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101820024B1 (en) 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 Combination of an insulin and a GLP-1 agonist
WO2010132508A2 (en) * 2009-05-11 2010-11-18 Biomatrica, Inc. Compositions and methods for biological sample storage
EP3345593B1 (en) * 2009-11-13 2023-09-06 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising despro36exendin-4(1-39)-lys6-nh2 and methionine
TR201809460T4 (en) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1-agonist, an insulin and methionine.
EA034869B1 (en) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Treatment of genotyped diabetic patients with dpp-4 inhibitors such as linagliptin
MX341025B (en) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Combination therapy.
CA2806734A1 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
US9376709B2 (en) 2010-07-26 2016-06-28 Biomatrica, Inc. Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures
ES2606554T3 (en) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the manufacture of a medication for the treatment of type 2 diabetes mellitus
KR102349549B1 (en) 2010-11-12 2022-01-11 넥타르 테라퓨틱스 Conjugates of an il-2 moiety and a polymer
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
JP6034798B2 (en) * 2010-12-02 2016-11-30 オンコリティクス バイオテク，インコーポレーテッド Liquid virus preparation
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI608847B (en) 2011-08-29 2017-12-21 賽諾菲阿凡提斯德意志有限公司 Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
CN103063829B (en) * 2012-12-21 2015-01-14 杭州茂天赛科技有限公司 Frozen stock solution
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3656215B1 (en) 2014-06-10 2021-08-04 Biomatrica, INC. Stabilization of thrombocytes at ambient temperatures
AU2015301936B2 (en) 2014-08-11 2019-03-07 Delinia, Inc. Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
PE20171622A1 (en) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland INSULIN GLARGIN / LIXISENATIDE FIXED RATIO FORMULATION
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
KR102589056B1 (en) 2015-12-08 2023-10-12 바이오매트리카 인코포레이티드 decreased erythrocyte sedimentation rate
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CN109310697A (en) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 The combination of Li Gelieting and melbine
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018089420A1 (en) 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
KR20200010354A (en) 2017-05-24 2020-01-30 팬디온 테라퓨틱스, 인코포레이티드 Targeted Immune Tolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
WO2019185705A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Il-2 conjugates
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
JP2023507115A (en) 2019-12-17 2023-02-21 アムジエン・インコーポレーテツド Dual interleukin-2/TNF receptor agonist for use in therapy
WO2021127487A2 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
CN115362168A (en) 2020-01-14 2022-11-18 辛德凯因股份有限公司 Methods and compositions for biasing IL2 muteins
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
AU2021286177A1 (en) 2020-06-03 2022-12-01 Ascendis Pharma Oncology Division A/S IL-2 sequences and uses thereof
TWI815194B (en) 2020-10-22 2023-09-11 美商基利科學股份有限公司 INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE
MX2023005458A (en) * 2020-11-13 2023-05-23 Jiangsu Hengrui Pharmaceuticals Co Ltd Pharmaceutical composition comprising human interleukin 2 variant or derivative thereof and use thereof.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60215631A (en) * 1984-04-09 1985-10-29 Takeda Chem Ind Ltd Interleukin-2 composition
EP0158487B1 (en) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
JPH0645551B2 (en) * 1986-01-07 1994-06-15 塩野義製薬株式会社 Interleukin-2 composition
JPH0229016A (en) * 1989-06-09 1990-01-31 Alpine Electron Inc Equalizer
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
AU8985898A (en) * 1997-07-31 1999-02-22 Rhodia Chimie Cosmetic composition comprising a functionalised polyorganosiloxane
DZ2788A1 (en) * 1998-05-15 2003-12-01 Bayer Ag Selective IL-2 agonists and antagonists.
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2

Also Published As

Publication number Publication date
CN1523997B (en) 2010-09-01
ES2344729T3 (en) 2010-09-06
SV2002000512A (en) 2002-07-03
JP2015007114A (en) 2015-01-15
JP2012211166A (en) 2012-11-01
CO5290308A1 (en) 2003-06-27
US6689353B1 (en) 2004-02-10
BR0112101B1 (en) 2017-11-14
CA2413334C (en) 2011-03-08
JP5522878B2 (en) 2014-06-18
JP2004532791A (en) 2004-10-28
KR20030016312A (en) 2003-02-26
MXPA03000046A (en) 2003-06-19
WO2002000243A3 (en) 2003-10-02
UY26805A1 (en) 2002-01-31
IL153587A0 (en) 2003-07-06
MY128629A (en) 2007-02-28
AR029139A1 (en) 2003-06-04
ECSP014106A (en) 2002-02-25
HN2001000139A (en) 2003-12-11
EP1370280A2 (en) 2003-12-17
JP5989728B2 (en) 2016-09-07
TWI235063B (en) 2005-07-01
EP1370280B1 (en) 2010-06-16
CU23536A3 (en) 2010-06-17
DOP2001000197A (en) 2003-01-15
DE60142412D1 (en) 2010-07-29
CN1523997A (en) 2004-08-25
CA2413334A1 (en) 2002-01-03
KR100799402B1 (en) 2008-01-30
IL153587A (en) 2007-12-03
WO2002000243A2 (en) 2002-01-03
BR0112101A (en) 2004-07-06
PE20020127A1 (en) 2002-04-27

Similar Documents

Publication Publication Date Title
AU2001273063A1 (en) Stabilized interleukin 2
AU2001262847A1 (en) Language-understanding
AU2001231532A1 (en) Improved interleukin 10
AU2001254546A1 (en) Aminopiperidines
AU2000267458A1 (en) Hypercomputer
AU2001239310A1 (en) Decahydro-isoquinolines
AU2001220246A1 (en) Neckphone
AU2001258349A1 (en) Bisacylguanidine
AU2001279754A1 (en) Indoloquinazolinones
AU2001281965A1 (en) Novel 6-phenylphenanthridines
AU2001258924A1 (en) Microsatellite-aflp
AU3724701A (en) Family 5 xyloglucanases
AU2001281921A1 (en) Bdellosomes
AU2001246864A1 (en) Hypotensors
AU2001245953A1 (en) Oncogenic osteomalacia-related gene 1
AU2001226668A1 (en) Crankshaft-starter-generator
AU2001260192A1 (en) Glycinamides
AU2001262711A1 (en) Cytoprotectors
AU2002221623A1 (en) Gene 4
AU2001275014A1 (en) Imidazoloisoquinolines
AU2001274750A1 (en) Novel beta-hydroxyamides
AU2001239750A1 (en) Haplotypes of the interleukin 15 gene
AU2001256287A1 (en) 2-phenyl-2h-pyridazine-3-ones
AU2001256521A1 (en) Golf-putters
AUPQ746000A0 (en) X-band 2000